Gapping down
In reaction to disappointing earnings/guidance: NATI -8.4%, GBX -5.6%, CPST -1.4%, WBA -1.1%, NG -1%
M&A news: AGN -19.3% (US Treasury issues inversion regulations and proposed earnings stripping regulations), PE -3.3% (acquires two properties in Southern Delaware for $359 mln in cash; updates guidance; commences 16 mln Class A common stock offering)
Select EU financial related names showing weakness: RBS -3.7%, DB -3.3%, CS -3.3%, BCS -3.2%, HSBC -3.2%, LYG-2.8%, SAN -2.3%, PUK -2.2%
Select oil/gas related names showing early weakness: RDS.A -2.8%, STO -2.7%, SDRL -2.7%, BP -2.4%, TOT -2%
Other news: PSUN -28.4% (rumors of potential Chapter 11 filing), TM -3.8% (like down due to Yen strength), TSLA -3.5% (Q1 delvieries 14820, below 16K guidance ), DIS -2.1% ( confirms COO Thomas Staggs to elave the company effective May 6 ), VRX -2.1% (terminates its sales team for its female libido pill Addyi, according to Bloomberg), SE -1.9% (prices offering of 14 mln shares of its common stock at $30 per share), AKR -1.5% ( commences ~3.6 mln public offering of common shares)
Analyst comments: CSCO -2.1% (downgraded to Neutral from Buy at BofA/Merrill), HRL -2.1% (downgraded to Underweight from Hold at BB&T Capital Mkts), BABY -1.2% (downgraded to Mkt Perform from Outperform at Raymond James)
In reaction to disappointing earnings/guidance: NATI -8.4%, GBX -5.6%, CPST -1.4%, WBA -1.1%, NG -1%
M&A news: AGN -19.3% (US Treasury issues inversion regulations and proposed earnings stripping regulations), PE -3.3% (acquires two properties in Southern Delaware for $359 mln in cash; updates guidance; commences 16 mln Class A common stock offering)
Select EU financial related names showing weakness: RBS -3.7%, DB -3.3%, CS -3.3%, BCS -3.2%, HSBC -3.2%, LYG-2.8%, SAN -2.3%, PUK -2.2%
Select oil/gas related names showing early weakness: RDS.A -2.8%, STO -2.7%, SDRL -2.7%, BP -2.4%, TOT -2%
Other news: PSUN -28.4% (rumors of potential Chapter 11 filing), TM -3.8% (like down due to Yen strength), TSLA -3.5% (Q1 delvieries 14820, below 16K guidance ), DIS -2.1% ( confirms COO Thomas Staggs to elave the company effective May 6 ), VRX -2.1% (terminates its sales team for its female libido pill Addyi, according to Bloomberg), SE -1.9% (prices offering of 14 mln shares of its common stock at $30 per share), AKR -1.5% ( commences ~3.6 mln public offering of common shares)
Analyst comments: CSCO -2.1% (downgraded to Neutral from Buy at BofA/Merrill), HRL -2.1% (downgraded to Underweight from Hold at BB&T Capital Mkts), BABY -1.2% (downgraded to Mkt Perform from Outperform at Raymond James)